Swiss health-tech Aeon raises €8.2m for AI-powered early disease detection platform
Swiss health-tech company Aeon has secured €8.2m in seed funding to develop what it describes as an advanced platform for early detection and preventive healthcare.
The company combines full-body MRI scans, blood biomarkers, and genetic analysis in a single 60-minute check-up, which it claims can detect and predict over 500 diseases and health risks.
Unlike consumer health platforms that typically use wearable devices or basic blood tests, Aeon’s approach integrates multiple data sources that are reviewed by board-certified physicians and discussed with a radiologist. The company says it has maintained a zero per cent false positive rate in clinical-grade follow-ups since launching in 2024.
Aeon uses AI for automated imaging analysis to detect anomalies on MRI scans, cross-validation to correlate different data types, and predictive modelling to generate personalised risk profiles for users.
The Global Alliance for Chronic Diseases reports that 41 million people die annually from non-communicable diseases, with this figure projected to rise by 27 per cent by 2030. The organisation notes that 80 per cent of these deaths are preventable.
Since its launch, Aeon reports detecting early-stage cancers, aneurysms, Alzheimer‘s, and other conditions in people who felt healthy. The company cites one case where a 56-year-old man with undiagnosed kidney cancer was identified through a single scan.
The platform has become the first health service offering full-body check-ups eligible for insurance reimbursement, with agreements signed with Switzerland’s largest providers including KPT. Customers can receive up to 80 per cent reimbursement depending on their plan.
The funding round was led by London-based venture capital firm Concentric, with participation from Calm/Storm Ventures, GoHub Ventures, Kadmos Capital, EWOR, and Swiss investor Daniel Gutenberg, who has backed 12 unicorns including Airbnb, Facebook and SumUp.
The capital will support Aeon’s expansion across Switzerland, Germany, and the UK, with additional international markets planned. The company intends to open more than 10 new locations and enhance partnerships with insurers and employers.
Aeon’s founding team includes chief executive Tim Seithe, who previously founded and sold Tillhub to Unzer, and chief product officer Samuel Frey, who brings experience from diagnostics company Platomics. Scientific advisor Dr Andreas Lemke is described as one of Europe’s leading MRI physicists and founder of brain imaging company Mediaire.
Seithe said: “We’re redefining preventive care by shifting it from reactive checks to proactive, personalised health management.
“Our approach goes beyond early disease detection — we’re tackling one of preventive medicine’s biggest challenges: false positives.
Every customer receives a tailored risk profile, along with a clear, medically grounded plan to monitor and reduce their health risks over time.
Alex Stroud, principal at Concentric, said: “Aeon is not just another testing solution.
2In our view, many consumer health products on the market today deliver questionable value.
“Validated by insurers, Aeon is delivering the most medically robust preventive health product on the market.
“That rare combination of clinical rigor and commercial scalability is what makes this team so exciting.”
